Zomedica acquires Revo Squared veterinary imaging assets for $6M cash plus earn-out and warrants

Zomedica Corp.

Base purchase price $6M cash, subject to working capital adjustments; $500K held in escrow for 15 months.
Up to $4M in earn-out payments based on net sales milestones ($2M each for $5M and $10M threshold) through 2027.
Warrants to purchase 10M common shares issued at closing; exercise price tied to ZOM closing price on closing date.
Acquisition includes MicroView digital cytology platform, an automated slide preparation and imaging system for veterinary clinics.
Closing expected on or around July 1, 2022; Revo Squared CEO Bill Campell and Senior Director Negin Ghassemian to join Zomedica.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.